Shire’s merger with Baxalta looks a little peaky by admin | Jan 13, 2016 | Uncategorized | 0 comments The drugmaker’s Chief Executive Flemming Ornskov has clinched his deal to buy haematology specialist Baxalta for $35 billion. The deal brings Shire scale in rare diseases, but offers few cost…